Revvity, Inc. (RVTY) Stock Analysis
Is RVTY a good investment?
Revvity, Inc. (RVTY) has a Plutrex AI rating of 46.0/100 as of August 22, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Balance sheet fortress: D/E of 0.38 vs. industry average 7.61 (95% less leverage), $1.02B cash, and $605M FCF — the cleanest balance sheet in the peer group with zero financial distress risk and significant strategic optionality. Main concern: Catastrophic valuation mismatch — now worse: P/E of 58.95x (up from 55.8x) on 8.57% five-year EPS growth (PEG 2.46, up from 2.33); stock at $124.75 now trades $2.13 ABOVE analyst consensus of $122.62, implying -1.7% downside; DCF fair value of $85-100 implies 20-32% downside; every valuation metric has deteriorated since the prior report.
Investment Summary
RVTY (Revvity) at $124.75 presents a deteriorating risk/reward profile versus my prior report 7 days ago. The stock has rallied +6.8% ($116.84 → $124.75) while the analyst consensus target rose only +1.3% ($121.00 → $122.62), meaning the stock now trades $2.13 ABOVE the analyst consensus — implying -1.7% downside to target. The valuation has worsened materially: P/E expanded from 55.8x to 58.95x (+5.6%) and PEG from 2.33 to 2.46 (+5.6%), while revenue growth remains unchanged at 1.3%. The core structural problem is unchanged and now worse: RVTY trades at 58.95x earnings while growing EPS at only 8.57% over five years (PEG 2.46), with historical revenue growth of just 1.3% vs. the industry's 19.85% — a 93.5% growth deficit. ROE of 3.21% vs. industry 18.36% confirms the business is destroying economic value relative to peers. News sentiment is genuinely positive (94.3/100) — Q2 earnings beat, raised full-year guidance, AI-enabled drug discovery orders, SuperFlex prenatal screening launch, and 'Signals for Startups' product — but these catalysts are incremental, not transformational. The stock has now overshot even the modest analyst target, making the current price indefensible on any valuation framework. HOLD remains the recommendation, but the entry zone for new buyers has not been reached — the stock is further from fair value than a week ago.
Key Strengths
- Balance sheet fortress: D/E of 0.38 vs. industry average 7.61 (95% less leverage), $1.02B cash, and $605M FCF — the cleanest balance sheet in the peer group with zero financial distress risk and significant strategic optionality
- Operational efficiency leader: Operating margin of 17.05% is 47.9% above the industry average of 11.53%, demonstrating superior cost discipline; Q2 2026 beat on both EPS and revenue with management raising full-year profit AND revenue guidance confirms execution quality
- Emerging growth catalysts: AI-enabled drug discovery workflow orders represent a genuine new growth vector; SuperFlex prenatal screening system launch targets structurally expanding preeclampsia market driven by demographic trends; 'Signals for Startups' product opens early-stage biotech channel
Key Concerns
- Catastrophic valuation mismatch — now worse: P/E of 58.95x (up from 55.8x) on 8.57% five-year EPS growth (PEG 2.46, up from 2.33); stock at $124.75 now trades $2.13 ABOVE analyst consensus of $122.62, implying -1.7% downside; DCF fair value of $85-100 implies 20-32% downside; every valuation metric has deteriorated since the prior report
- Structural growth deficit vs. peers — unchanged: Revenue growth 1.3% vs. industry 19.85% (93.5% below peers), forward 5-year EPS growth 8.57% vs. industry 21.36% (59.9% below peers), ROE 3.21% vs. industry 18.36% (82.5% below peers) — RVTY is a growth laggard now trading above analyst consensus, making it the worst risk/reward proposition in the peer group
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
RVTY's fundamentals are structurally challenged despite pockets of operational strength. Gross margin of 48.2% (vs. industry 48.1% — essentially at parity) shows competitive product economics, but the cascade to operating margin of 17.1% (vs. industry 11.5% — a genuine +47.9% advantage) and net margin of 8.2% (vs. industry 7.5%) reveals significant below-the-line cost drag. The ROE of 3.21% vs. industry 18.36% is the most damning metric — 82.5% below peers despite better operating margins, indicating the balance sheet is bloated with acquisition goodwill/intangibles that generate inadequate returns. P/E of 58.95x vs. industry 56.9x (3.6% premium) is unjustifiable given RVTY's 5-year forward EPS growth of 8.57% vs. industry 21.36% — RVTY grows at 40% of the industry rate but trades at a premium multiple. PEG of 2.46 vs. industry 2.39 (2.9% premium) is even more alarming on a growth-normalized basis. Historical revenue growth of 1.3% vs. industry 19.85% and earnings growth of 1.2% vs. industry 47.15% confirm structural stagnation. The balance sheet is the standout positive: D/E of 0.38 vs. industry 7.61 (95% less leverage), $1.02B cash, and $605M FCF provide exceptional financial resilience. DCF fair value remains $85-100/share at growth-justified multiples (18-20x forward EPS for a 9-10% grower), implying 20-32% downside from current $124.75.
News Sentiment
Revvity is firing on all cylinders operationally — but the stock may have gotten ahead of itself. The medical diagnostics company delivered a strong second quarter, beating earnings expectations and promptly raising its full-year profit and revenue forecasts, according to its Q2 2026 financial results announcement. That's the kind of news that gets investors excited, and it shows in the stock's 6.8% surge over the past week. The company is also making smart strategic moves. Revvity launched its SuperFlex Prenatal Screening System, targeting smaller labs that previously lacked access to advanced preeclampsia screening — a market that's growing as more women are having children later in life and diabetes rates rise globally. Meanwhile, the company's new 'Signals for Startups' initiative is courting early-stage biotech companies, planting seeds in what could become a lucrative customer base as AI-driven drug discovery accelerates. Speaking of AI — Revvity is seeing real orders tied to AI-enabled drug discovery workflows, suggesting the technology revolution in pharmaceuticals is translating into actual revenue, not just hype. The diagnostics segment in particular showed strong growth that drove the Q2 outperformance. The story sounds great. The problem? At $124.75, the stock has actually surpassed what Wall Street analysts think it's worth — their consensus target is $122.62. Great execution is already priced in, and then some.
Risk Assessment
PRIMARY RISK: Valuation compression. At P/E 58.95x with 8.57% EPS growth, any multiple normalization toward a growth-justified 18-22x would imply 60-70% downside to $50-75/share — an extreme scenario but mathematically possible in a risk-off environment. SECONDARY RISK: Growth disappointment. With revenue growing at only 1.3% historically, any miss on the raised 2026 guidance could trigger sharp multiple compression. The Q2 beat and raised guidance are positive but create a higher bar for Q3/Q4. TERTIARY RISK: Stock now above analyst consensus ($124.75 vs. $122.62 target) — professional analysts see no upside from here, and any target price cuts would be incrementally negative. MITIGATION: The $1.02B cash position and $605M FCF provide a fundamental floor; the company is not at risk of financial distress. The AI drug discovery and prenatal screening catalysts could accelerate growth toward industry rates over 2-3 years, potentially justifying higher multiples. POSITION SIZING: Reduce to 2.0% max given stock is above analyst target — do not add at current levels. Only initiate/add in the $95-$102 entry zone where risk/reward improves to 2.3:1.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is RVTY a halal stock?
No, Revvity, Inc. (RVTY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for RVTY?
Revvity, Inc. (RVTY) has a Plutrex AI rating of 46.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is RVTY a good investment?
According to Plutrex AI, RVTY has a Hold rating (46.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in RVTY?
US stocks like RVTY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in RVTY?
Plutrex AI identifies the main risks for RVTY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.